Lytix Biopharma to host Capital Markets Day

Save the date; June 1, 2022

Ted White,
CEO, Verrica



Gary Goldenberg,
CMO, Verrica

Aurelien Marabelle,
Visiting professor
at Stanford University

Øystein Rekdal,
CEO, Lytix

- Lytix Biopharma ("Lytix"), is pleased to announce that it will host a Capital Markets Day for investors, analysts and media on Wednesday, June 1, 2022.
- The event will be open for physical attendance in Oslo, Norway, as well as a live webcast. It is scheduled to start at 14.00 CET, and is expected to last approximately two hours, including Q&A.
- Speakers will be Ted White, CEO of Verrica Pharmaceuticals Inc. ("Verrica"), Gary Goldenberg, CMO of Verrica, Aurelien Marabelle, visiting professor at Stanford University and an internationally recognized expert on intratumoral cancer treatment, and Øystein Rekdal, CEO of Lytix Biopharma.
- Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize its lead compound, LTX-315, for dermatologic oncology conditions, and the first patient has been dosed in Verrica's Phase II study evaluating LTX-315 for intratumoral treatment of basal cell carcinoma (skin cancer). At the CMD the focus will be on the rationale and current state-of-the-art regarding intratumoral treatment of cancer patients. Most of all, the agreement between Verrica and Lytix and the commercial opportunity for and clinical value of LTX-315 in treatment of cell carcinomas will be highlighted.
- Further details of the agenda and registration details will follow.

Lytix Biopharma is a clinical-stage biotech company with a world leading, first-in-class *in situ* vaccination technology platform and drug candidates in three independent Phase II clinical trials, supported by firm scientific, commercial and financial validation.

Lytix Biopharma

Lytix Biopharma AS, Sandakerveien 138, 0484 Oslo, Norway|www.lytixbiopharma.com|Øystein Rekdal (CEO) oystein.rekdal@lytixbiopharma.com, m +47 975 73 358

Lytix Biopharma is a clinical-stage biotech company with a world leading, first-in-class *in situ* vaccination technology platform and candidate drugs in three independent Phase II clinical trials, supported by firm scientific, commercial and financial validation.

FIRST IN CLASS

- Lytix' products represent an emerging class of cancer drugs with a universal mechanism of action
- After intratumoral injection, Lytix' drug candidates release both tumor antigens and immune-stimulating molecules, inducing immunogenic cell death
- The result of this dual mechanism of action is the priming of a broad range of T cells and increased T-cell activation and infiltration, turning cold tumors hot
- Lytix' drugs candidates sensitize tumors to other therapies, and enables a cornerstone position within cancer immunotherapy

HETEROGENEITY - A MAJOR CLINICAL CHALLENGE

- Tumor heterogeneity introduces significant challenges in cancer therapy and is the main cause of treatment failure, drug resistance, relapse and recurrence
- Lytix' oncolytic molecules uniquely address heterogeneity by being able to recognize and target the different cancer subclones in a heterogenous tumor, including both drug sensitive and resistant cancer cells
- The unique killing mode of action results in the release of a plethora of neoantigens from the different cancer cell clones

LEAD COMPUND OUTLICENSED TO VERRICA

- Lytix' commercial partner, Verrica Pharmaceuticals Inc., brings LTX-315 into treatment of certain skin cancers
- Recruitment in Verrica's Phase II study for patients with basal cell carcinoma commenced in Q1 2022
- More than 4 million patients are diagnosed with this disease in U.S. yearly
- Lytix maintains all other rights to LTX-315
- The license deal entitles Lytix potentially to receive aggregated milestone payments in excess of $ 100 mill. and sales royalties in the range of 10 – 15 %

LTX-315 IN MULTIPLE PHASE II STUDIES

- Exploratory ATCT study completed, data to be presented at ASCO 2022
- Monotherapy study in basal cell carcinoma running in U.S.
- Combination study with pembrolizumab launched at MD Anderson CC in 2021

A DEVELOPMENT PROGRAM WITH 4 PILLARS

- Two Phase II trials for LTX-315 ongoing in the US:
  - Phase II combination study with pembrolizumab launched in 2021
  - Verrica Pharmaceuticals Inc.'s Phase II study in skin cancers recruiting from Q1 2022
- LTX-401 – a follow-up compound developed for deeper seated lesions - to complete preclinical phase in 2022
- An explorative program for the adoptive T-cell transfer setting with Phase II study in completion
- Early-stage undisclosed investigation of oncolytic molecules in a specific clinical setting ongoing

A TEAM AND TECHNOLOGY WITH FIRM VALIDATION

- Academic collaborations with world leading immuno-oncology scientists
- Nobel laureate Jim Allison at Lytix' Scientific Board
- Ongoing clinical study in U.S. led by #1 cancer hospital globally, MD Anderson Cancer Center
- Commercial deal with Verrica Pharmaceuticals Inc.
- US Life Science investor PBM Capital as cornerstone investor

FINANCIAL SITUATION AND STRATEGIC PRIORITIES

- Cash position by the end of 2021 at 22 MUSD
  - Funding for the Phase II trials in place
- Priorities for 2022
  - Complete recruitment in Phase II combination study
  - Execute the preclinical program for LTX-401
  - Evaluate use of oncolytic molecules in ATCT setting
  - Accelerate the progression of the unique platform, building a strong pipeline of oncolytic molecules for intratumoral injection
- Listed and traded at Euronext Growth, ticker LYTIX.OL

Lytix Biopharma

Lytix Biopharma AS, Sandakerveien 138, 0484 Oslo, Norway|www.lytixbiopharma.com|Øystein Rekdal (CEO) oystein.rekdal@lytixbiopharma.com, m +47 975 73 358